INSM1 immunostaining in solid papillary carcinoma of the breast.
INSM1 protein
breast neoplasms
neuroendocrine
notch
solid papillary carcinoma
Journal
Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
09
03
2020
accepted:
19
10
2020
pubmed:
7
11
2020
medline:
15
10
2021
entrez:
6
11
2020
Statut:
ppublish
Résumé
Solid papillary carcinoma (SPC) is a histological subtype of breast carcinomas. At least 50% of SPC show neuroendocrine differentiation. Insulinoma-associated protein 1 (INSM1) is a transcription factor now employed as a useful neuroendocrine marker. It is suppressed by the Notch signaling pathway in other neuroendocrine tumors. However, the usefulness of INSM1 as a neuroendocrine marker and the relationships between INSM1 and NOTCH receptors in SPC of the breast currently remain unclear. To clarify the usefulness of INSM1 as a neuroendocrine marker and the relationships between INSM1 and NOTCH receptors in SPC, we performed immunohistochemistry using 19 tissue specimens of SPC of the breast. We complementarily analyzed public RNA sequencing data on breast carcinomas. Immunohistochemical examinations revealed that the staining intensity of INSM1 was significantly higher in the neuroendocrine group than in the non-neuroendocrine group. Positive correlations were observed between INSM1 and synaptophysin (SYP), or chromogranin-A (CHGA). In all cases, NOTCH 2 and 3 were positive, while NOTCH 1 and 4 were negative. According to public RNA data analyses, there were positive correlations between INSM1 and SYP, or CHGA, and negative correlations between INSM1 and NOTCH1-3. INSM1 is useful as a diagnostic marker for SPC with neuroendocrine differentiation in the breast.
Substances chimiques
Biomarkers, Tumor
0
Receptors, Notch
0
Repressor Proteins
0
INSM1 protein, human
147955-03-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-59Informations de copyright
© 2020 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
Références
Allison KH, Brogi E, Ellis IO et al. Epithelial tumours of the breast. In: The WHO Classification of Tumours Editorial Board, ed. WHO Classification of Tumours of the Breast, 5th edn. Lyon: International Agency for Research on Cancer, 2019; 9-161.
Roininen N, Takala S, Haapasaari KM et al. Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: A retrospective clinical study. BMC Cancer 2017; 17: 1-7.
Miremadi A, Pinder SE, Lee AHS et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 2002; 40: 215-22.
Rovera F, Lavazza M, Rosa SL et al. Neuroendocrine breast cancer: Retrospective analysis of 96 patients and review of literature. Int J Surg 2013; 11: S79-83.
Zhang Y, Chen Z, Bao Y et al. Invasive neuroendocrine carcinoma of the breast: A prognostic research of 107 Chinese patients. Neoplasma 2013; 60: 215-22.
Maluf HM, Koerner FC. Solid papillary carcinoma of the breast: A form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. Am J Surg Pathol 1995; 19: 1237-44.
Otsuki Y, Yamada M, Shimizu S et al. Solid-papillary carcinoma of the breast: Clinicopathological study of 20 cases. Pathol Int 2007; 57: 421-29.
Guo S, Wang Y, Rohr J et al. Solid papillary carcinoma of the breast: A special entity needs to be distinguished from conventional invasive carcinoma avoiding over-treatment. Breast 2016; 26: 67-72.
Nassar H, Qureshi H, VolkanAdsay N et al. Clinicopathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinomas. Am J Surg Pathol 2006; 30: 501-507.
Kawasaki T, Nakamura S, Sakamoto G et al. Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast - comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases. Histopathology 2008; 53: 288-98.
Goto Y, De Silva MG, Toscani A et al. A novel human insulinoma-associated cDNA, IA-1, encodes a protein with “zinc-finger” DNA-binding motifs. J Biol Chem 1992; 267: 15252-57.
Breslin MB. Neuroendocrine differentiation factor, IA-1, is a transcriptional repressor and contains a specific DNA-binding domain: Identification of consensus IA-1 binding sequence. Nucleic Acids Res 2002; 30: 1038-45.
Gierl MS, Karoulias N, Wende H et al. The Zinc-finger factor Insm1 (IA-1) is essential for the development of pancreatic β cells and intestinal endocrine cells. Genes Dev 2006; 20: 2465-78.
Fujino K, Motooka Y, Hassan WA et al. Insulinoma-associated protein 1 is a crucial regulator of neuroendocrine differentiation in lung cancer. Am J Pathol 2015; 185: 3164-77.
Fujino K, Yasufuku K, Kudoh S et al. INSM1 is the best marker for the diagnosis of neuroendocrine tumors: Comparison with CGA, SYP and CD56. Int J Clin Exp Pathol 2017; 10: 5393-405.
Rosenbaum JN, Guo Z, Baus RM et al. A novel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am J Clin Pathol 2015; 144: 579-91.
Takase Y, Naito Y, Okabe Y et al. Insulinoma-associated protein 1 expression in pancreatic neuroendocrine tumours in endoscopic ultrasound-guided fine-needle aspiration cytology: An analysis of 14 patients. Cytopathology 2019; 30: 194-200.
Ito T, Udaka N, Yazawa T et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 2000; 127: 3913-21.
Roy M, Buehler DG, Zhang R et al. Expression of insulinoma-associated protein 1 (INSM1) and orthopedia homeobox (OTP) in tumors with neuroendocrine differentiation at rare sites. Endocr Pathol 2019; 30: 35-42.
Wolff AC, Hammond MEH, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society Of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med 2014; 138: 241-56.
Hirsch FR, Varella-Garcia M, Bunn PA et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-807.
cBioPortal for Cancer Genomics (homepage on the Internet). New York, NY, USA: Memorial Sloan Kettering Cancer Center; c2010-2020. Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016); July 24 2016. (Accessed 5 March 2020). Available from: https://www.cbioportal.org/study/summary?id=brca_metabric
Mukhopadhyay S, Dermawan JK, Lanigan CP et al. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: An immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod Pathol 2019; 32: 100-109.
Fisher ER, Palekar AS. Solid and mucinous varieties of so-called mammary carcinoid tumours. Am J Clin Pathol 1979; 72: 909-16.
Kawasaki T, Kondo T, Nakazawa T et al. Is CD56 a specific and reliable neuroendocrine marker for discriminating between endocrine/neuroendocrine ductal carcinoma in situ and intraductal papilloma of the breast? Pathol Int 2011; 61: 49-51.
Kidd S, Kelley MR, Young MW. Sequence of the notch locus of Drosophila melanogaster: Relationship of the encoded protein to mammalian clotting and growth factors. Mol Cell Biol 1986; 6: 3094-108.
Jarriault S, Brou C, Logeat F et al. Signalling downstream of activated mammalian Notch. Nature 1995; 377: 355-58.
Reedijk M, Odorcic S, Chang L et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005; 65: 8530-37.
Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia 2004; 9: 145-63.